Patient organ and effective dose estimation in radionuclide therapy with ²²³Ra -dichloride

Radionuclide therapy with ²²³Ra-dichloride is used to treat bone metastases and to improve the quality of life of patients with metastatic castration-resistant prostate cancer. At the present time there is no reliable data on the biodistribution of the ²²³Ra-dichloride in the patient body. The aim of this study was to assess absorbed, equivalent doses in radiosensitive organs and tissues and effective dose from internal exposure for patients with metastatic castration-resistant prostate cancer treated with ²²³Ra-dichloride. Internal doses from ²²³Ra-dichloride were calculated for a chamber model specific for patients with metastatic castration-resistant prostate cancer. This model consists of 8 chambers (blood plasma, two chambers describing bone tissue, small intestine, upper large intestine, lower large intestine, feces and the rest of the body). Time-integrated activities were calculated using the SAAM II v2.3 software. The IDAC-Dose 2.1 software was used to calculate the absorbed doses. The highest absorbed doses in organs and equivalent doses were determined for the bone surface and red bone marrow. The absorbed dose from a-radiation in the bone surface for a set of six therapeutic procedures with ²²³Ra-dichloride was estimated as 1 Gy; in the red bone marrow — 0.14 Gy. However, the approach used does not specifically consider accumulation of the radiopharmaceutical in metastases, which can lead to a significant overestimation of the absorbed dose in the healthy part of the bone surface and red bone marrow.

1. Caprin AD, Starinsky VV, Petrov GV. Malignant neoplasms in Russia in 2018 (morbidity and mortality). Moscow: MNIOI after P.A. Herzen is a branch of the Federal State Budgetary Institution “NMITs of Radiology” of the Ministry of Health of Russia 2019. 250 p. (In Russian)

2. Scher H, Morris M, Stadler W, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. Journal of Clinical Oncology. 2016;34(12): 1402-18.

3. Chipiga LA, Vodovatov AV, Petrova AE, Stanzhevsky AA. Analysis of 223Ra-dichloride biodistribution models for assessing internal exposure doses. Formulas of Pharmacy. 2020;2(1): 54-69 (In Russian)

4. Taprogge J, Murray I, Gear J, Chittenden SJ. Compartmental model for 223Ra-Dichloride in patients with metastatic bone disease from castration-resistant prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 2019; 1-9.

5. Lassmann M, Lassmann M, Nosske D. Dosimetry of 223Ra-Chloride: dose to normal organs and tissues. European Journal of Nuclear Medicine and Molecular Imaging. 2012;40(2): 207-212.

6. ICRP Publication 20. Alkaline Earth Metabolism in Adult Man. Pergamon Press, Oxford. 1973; 423 p.

7. ICRP Publication 67. Age-dependent doses to members of the public from intake of radionuclides. Part 2. Ingestion dose coefficients. Annals of the ICRP. 1993;23(3-4).

8. ICRP Publication 137. Occupational Intakes of Radionuclides: Part 3. Annals of the ICRP. 2018;46(3-4).

9. Barrett PH, Bell BM, Cobelli C. SAAM II: simulation. analysis. and modeling software for tracer and pharmacokinetic studies. Metabolism. 1998;47(4): 484-492.

10. Data analysis software OriginLab [Internet]. Available from: https://www.originlab.com/demodownload.aspx [Accessed 16.08.2020]

11. Andersson M, Johansson L, Minarik D. An internal radiation dosimetry computer program. IDAC 2.0. for estimation of patient dose for radiopharmaceuticals. Radiation Protection Dosimetry. 2014;162: 299-305.

12. ICRP Publication 107. Nuclear Decay Data for Dosimetric Calculations. Annals of the ICRP. 2008;38(3): 96.

13. Dauer LT, Williamson MJ, Humm J, O’Donoghue J, Ghani R, Awadallah R, et. al. Radiation Safety Considerations for the Use of 223RaCl2 DE in Men with Castration-resistant Prostate Cancer. Health Physics. 2014;106: 494-504.

14. Snyder WS, Ford MR, Warner GG. Estimates of Specific Absorbed Fractions for Photon Sources Uniformly Distributed in Various Organs of a Heterogeneous Phantom. Medical Internal Radiation Dose Committee (NM/MIRD) Pamphlet No. 5, revised. Society of Nuclear Medicine. New York, NY. 1978. 52 p.

15. Bruland 0, Nilsson SS, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alphaemitter 223Ra: adjuvant or alternative to conventional modalities? Clinical Cancer Research. 2006; 6250-6257.

16. Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et. al. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alphaparticle emitters for targeted radionuclide therapy. Journal of Nuclear Medicine. 2010;51: 311-328.

17. Howell RW, Goddu SM, Narra VR, Fisher DR, Schenter RE, Rao DV, et. al. Radiotoxicity of gadolinium-148 and ra-dium-223 in mouse testes: relative biological effectiveness of alpha-particle emitters in vivo. Radiation Research. 1997;147: 342-348.

18. International Commission on Radiological Protection. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication 103. «Alana»; 2009. 312 p. (In Russian)

19. International Commission on Radiological Protection. 1991 recommendation of the International Commission on Radiological Protection. ICRP Publication 60. Annals of the ICRP. 1991;21(1-3).

20. Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, et al. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2017;45(5): 824-845.

21. Chittenden SJ, Hindorf C, Parker CC, Lewington VJ, Pratt BE , Johnson B, et al. A Phase 1. Open-Label Study of the Biodistribution Pharmacokinetics and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases. Journal of Nuclear Medicine. 2015;56: 1304-1309.

22. Hobbs RF, Song H, Watchman CJ, Bolch WE, Aksnes AK, Ramdahl T, et al. A bone marrow toxicity model for Ra-223 aemitter radiopharmaceutical therapy. Physics in Medicine and Biology. 2012;57: 3207-3222.

23. Ministry of Health of the Russian Federation “Instructions for the medical use of the drug Xofigo”. 17 p. (In Russian)

24. Uselmann AJ, Thomadsen BR. On effective dose for radiotherapy based on doses to nontarget organs and tissues. Medical Physics. 2015;42(2): 977-982.

25. Radiation Protection and Safety of Radiation Sources: International Basic Safety Standards GSR Part 3. IAEA, Vienna; 2015. 518 p. (In Russian)

26. International Commission on Radiological Protection. Radiological Protection in Ion Beam Radiotherapy. ICRP Publication 127. Annals of the ICRP. 2014;43(4): 5-113.

27. International Commission on Radiological Protection. Preventing Accidental Exposures from New External Beam Radiation Therapy Technologies. ICRP Publication 112. Annals of the ICRP. 2009;39(4): 1-2.

28. Loreti G, Delis H, Healy B, Izewska J, Poli GL, Meghzifene A. IAEA education and training activities in medical physics. Medical Physics International Journal. 2015;3(2): 81-86.